What if we found cancer early enough to make a difference
Galleri®, a multi-cancer early detection test, can help you screen for many of the deadliest cancers that don’t have recommended screening today, including pancreatic, esophageal, ovarian, and liver.** It’s available as a covered benefit to eligible Intermountain Health caregivers and dependents (e.g., spouse, domestic partner).
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests. False positive and false negative results do occur.
**Sensitivity in study participants with - Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV).Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV).Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV).Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Galleri should be used in addition to healthcare provider recommended screening tests. False positive and false negative results do occur.
**Sensitivity in study participants with - Pancreas cancer: 83.7% overall (61.9% stage I, 60.0% stage II, 85.7% stage III, 95.9% stage IV).Esophagus cancer 85.0% overall (12.5% stage I, 64.7% stage II, 94.7% stage III, 100% stage IV).Ovary cancer: 83.1% overall (50.0% stage I, 80.0% stage II, 87.1% stage III, 94.7% stage IV).Liver/bile duct cancer: 93.5% overall (100% stage I, 70.0% stage II, 100% stage III, 100% stage IV).
Request the Galleri Test
Visit with an Intermountain Health Provider to discuss getting the Galleri Test.
Galleri is by prescription only.
What is the Galleri Test
Overview of how the test works
Key benefits of the Galleri test
Do more to screen for cancer
Screen for many of the deadliest cancers, including cancers without recommended screening tests.1
Testing with ease
Completed with a simple blood draw.
Actionable results
If a cancer signal is found, the results provide prediction for the cancer signal origin to help guide next steps for diagnosis.
The Galleri test is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.
Galleri should be used in addition to healthcare provider recommended screening tests.
Our testing process
Request the Galleri test
Intermountain Primary Care Provider
Intermountain Connect Care-Primary Care Provider
Intermountain Employee Clinic in Murray, UT
Galleri is by prescription only.
Provide a blood sample
Once your test has been approved and ordered by a provider, visit an Intermountain lab or one of GRAIL's laboratory partners, to complete your blood draw.
Receive your test result
Your Intermountain provider will share your results about two weeks after your blood draw.
The Galleri test identifies DNA in the bloodstream shed by cancer cells and does not predict future genetic risk for cancer. The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends.
If you are eligible for this covered benefit, the test is accessible at no cost. However, in the event of a “Cancer signal detected” test result you may be responsible for out of pocket costs for necessary follow-up care your provider may recommend. Please contact your health insurance plan to determine covered expenses and your potential costs.
Frequently Asked Questions
The Galleri test is available to Intermountain caregivers through two options:
- Eligible caregivers and dependents (e.g., spouse, domestic partner) on the Intermountain Health employee medical plan through Select Health, age 50 or older, and who reside in Utah, can receive the Galleri test at no cost every 24 months.
- Individuals* who do not meet the above criteria, can still request the Galleri test through an Intermountain provider and self pay. Please note that this cost is a Health FSA or HSA eligible expense. The self pay cost is $949 and an invoice will be sent directly to you from GRAIL.
*The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Individuals must reside in the United States to be eligible. Galleri is by prescription only.
The Galleri test is available at no cost to eligible Intermountain Health caregivers and dependents (e.g., spouse, domestic partner) on the Intermountain Health employee medical plan through Select Health, age 50 or older, and who reside in Utah.
Additional costs may be incurred with any follow-up testing that may be necessary after receiving the Galleri test results.
You may meet with a Virtual Primary Care Provider via video visit to request the Galleri test. If you prefer in-person care, please see options listed below:
- Intermountain Primary Care Provider
- Intermountain Connect Care-Primary Care Provider
- Intermountain Employee Clinic in Murray, UT
How to schedule virtually:
1. Open Intermountain Health Patient Portal in the app or your web browser
2. Log in, create an account, or call 877-777-4023 to schedule
3. After logging in, scroll down to Virtual Primary Care and click Schedule Appointment
4. Make your scheduling selections
5. When asked, "What is the reason for your appointment?” enter “Galleri”
6. Confirm and book!
Virtual Primary Care visits are included as part of the Galleri test benefit for eligible Intermountain Health caregivers and dependents (e.g. spouse/domestic partner). If you are requesting the Galleri test as part of your annual wellness checkup, your visit will be covered 100% under your preventative care coverage through Select Health. Visits for the Galleri test outside of Virtual Primary Care visits or annual wellness checkups are not covered.
Yes, if you are eligible to receive the test. However, please check with your affiliated or non-Intermountain provider to determine whether they can offer the Galleri test. Alternatively, you can schedule a telehealth appointment with an Intermountain provider.
Please keep in mind if you are eligible to receive the test as a covered benefit and the blood sample is drawn from a non-Intermountain lab you may incur additional fees.
Eligible caregivers and dependents (e.g., spouse, domestic partner) on the Intermountain Health employee medical plan through Select Health, age 50 or older, and who reside in Utah, can receive the Galleri test at no cost every 24 months.
The Galleri test is a multi-cancer early detection test that detects DNA shed into the blood by many of the deadliest cancers, including cancers without recommended screening tests today, through s simple blood draw. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.
Galleri should be used in addition to healthcare provider recommended screening tests.
The Galleri test identifies DNA in the bloodstream shed by cancer cells at the time of your blood draw. If a cancer signal is detected, Galleri can predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Family history is only one of many risk factors associated with cancer development. Age is the most important risk factor for cancer. Other risk factors include lifestyle factors (smoking, elevated body mass index), hereditary cancer syndrome or genetic mutation with increased cancer risk, Infections (HPV, HIV, hepatitis) and others.
In a clinical validation study (CCGA3*), the Galleri test detected a signal shared by more than 50 types of cancer across all stages.
*Circulating Cell-Free Genome Atlas (CCGA) sub-study
Galleri detects a signal shared by multiple cancers. Using the Galleri test alongside recommended cancer screening programs, gives you the opportunity to do more to screen for cancer. Recommended routine cancer screening tests such as colonoscopy or mammograms have been shown to reduce cancer deaths.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Missing recommended screening or ignoring symptoms could lead to a delayed diagnosis of cancer.
Based on data from our studies, the Galleri test has shown a low false-positive rate of 0.5% (detects a cancer signal when no cancer is present). This means that in approximately 200 people without cancer tested 1 person would be expected to receive a false positive result.
The Galleri test development was supported by what is believed to be one of the largest clinical study programs in genomic medicine, with over 20,000 participants at more than 140 clinical study sites, including Intermountain Healthcare, Dana-Farber Cancer Institute, Cleveland Clinic, Sutter Health, OHSU, and U.S. Oncology Network. The studies have been published and the results can be reviewed.
The Galleri test has not been cleared or approved by the US Food and Drug Administration (FDA). Galleri is a laboratory developed test (LDT). A LDT is defined as a diagnostic test that is used within a single laboratory. FDA has oversight of LDTs; premarket approval of an LDT is generally not required. The Galleri test was developed, and its performance characteristics were determined by GRAIL.
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing.
Start by making an appointment with an Intermountain primary care provider. During your visit, your provider can order the Galleri test for you if appropriate. If you don’t have an Intermountain primary care provider, here are options:
- Intermountain Primary Care Provider
- Intermountain Connect Care-Primary Care Provider
- Intermountain Employee Clinic in Murray, UT
Once the test has been ordered, you will either be given a Galleri kit at your appointment or one will be shipped to you. Then take your kit to the nearest Intermountain lab or one of GRAIL's laboratory partners, to complete your blood draw.
Your provider will share the test results about two weeks after completing your blood draw.
No preparation or fasting is required for the Galleri test.
Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes typically from a vein in your arm.
It takes about two weeks after your blood draw to receive your test results from the provider who ordered your test.
Your result should be available to the provider who ordered your test within 10 business days (Mon — Fri excluding holidays) from the time your sample is received at the GRAIL laboratory. Your sample will arrive at the lab one to two business days after your blood draw.
If you no longer wish to receive your Galleri results, please contact your provider.
If you require further assistance, please contact GRAIL Customer Service at customerservice@grail.com or (833) 694‑2553.
This means that no cancer signal was found. Although the Galleri test did not find a cancer signal in your blood, this does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. This result does not predict whether you will develop cancer in the future. Missing routine screenings or ignoring symptoms can lead to a delayed diagnosis of cancer.
The Galleri test detected DNA methylation patterns that are often associated with cancer in your blood sample. In a clinical study, on average, 4 out of 10 people with a Cancer Signal Detected result received a cancer diagnosis.
A Cancer Signal Detected result is NOT a diagnosis of cancer. Diagnostic testing by a healthcare provider is needed to confirm if you have cancer. To help guide diagnostic evaluation, Galleri result includes one or two Cancer Signal Origin (CSO) predictions. The CSO prediction offers information about the tissue type or organ associated with the Cancer Signal to help guide next step.
Galleri is a screening test that identifies DNA in the bloodstream shed by cancer cells. A Cancer Signal Detected result is NOT a diagnosis of cancer. Diagnostic testing by a healthcare provider is needed to confirm if you have cancer. To help guide diagnostic evaluation, Galleri result includes one or two Cancer Signal Origin (CSO) predictions. The CSO prediction offers information about the tissue type or organ associated with the Cancer Signal.
The Galleri test is not a diagnostic test. Additional tests ordered by your primary healthcare provider are needed to confirm if cancer is present which may include blood work or imaging.
If a diagnostic evaluation after a Cancer signal detected result with Galleri does not confirm cancer, employees may be eligible for a complementary retest with Galleri.
The request for a retest must be submitted by the healthcare provider who will order the retest. The retest must be administered within 3 – 6 months after the initial Galleri test. To initiate a request for a re-test, the healthcare provider who will order the retest, should contact GRAIL Customer Service at (833) 694‑2553 or customerservice@grail.com. Customer Service hours are Monday through Friday 5:00 AM — 5:00 PM PT.
The Galleri test identifies DNA in the bloodstream shed by cancer cells at the time your blood is drawn, but you may develop cancer in the future. The test does not measure your risk of developing cancer in the future. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.
If you are on the Intermountain Health Employee Medical Plan through Select Health the Galleri test is a covered benefit every 24 months.
The provider who orders the test will receive your test result and share it with you. Your test result and medical information are confidential, and access is limited to individuals who need the information for a specific purpose.
Your employer will only receive de-identified information combined for all caregivers and will not receive individual results.
Visit our Provider Resource page for more information.
Get support
For questions about the Galleri test, please contact GRAIL Customer Service at (833) 694‑2553 or by email at customerservice@grail.com.
Questions about eligibility or benefits? Contact Select Health at 800−538−5038.
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.